Cargando…

Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies

BACKGROUND: Programmed cell death-1 (PD-1) inhibitor-related hematologic toxicities are a category of rare but clinically serious and potentially life-threatening adverse events; however, little is known about their risks across different treatment regimens and tumor types. The objective of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sui, Jiang-Dong, Wang, Ying, Wan, Yue, Wu, Yong-Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996859/ https://www.ncbi.nlm.nih.gov/pubmed/29922039 http://dx.doi.org/10.2147/DDDT.S167077

Ejemplares similares

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials
por: Zhou, Jian xin, et al.
Publicado: (2017)

The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis
por: Shi, Zuolin, et al.
Publicado: (2022)

Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
por: Cheng, Ying, et al.
Publicado: (2021)

The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis
por: Zhang, Jingyi, et al.
Publicado: (2021)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: He, Shukang, et al.
Publicado: (2021)

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
por: Alecu, Iulian, et al.
Publicado: (2018)

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
por: Zhao, Bin, et al.
Publicado: (2017)

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
por: Abedin, Sameem M, et al.
Publicado: (2016)

Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
por: Liang, Yuehua, et al.
Publicado: (2022)

The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis
por: Li, Mingkai, et al.
Publicado: (2020)

Risk factors for hematological toxicity of chemotherapy for bone and soft tissue sarcoma
por: OUYANG, ZHENGXIAO, et al.
Publicado: (2013)

Correction: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
por: Zhao, Bin, et al.
Publicado: (2019)

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
por: Bowling, Gartrell C., et al.
Publicado: (2023)

Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors
por: Schwab, Alfred, et al.
Publicado: (2022)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
por: Liao, Pei-Fei, et al.
Publicado: (2023)

Hematological and liver toxicity of anti-tuberculosis drugs
por: Mirlohi, Maryam-Sadat, et al.
Publicado: (2016)

Mechanistic models for hematological toxicities: Small is beautiful
por: Deyme, Laure, et al.
Publicado: (2021)

A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management
por: Lopez, Adriana T., et al.
Publicado: (2018)

Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors
por: Fattizzo, Bruno, et al.
Publicado: (2022)

The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis
por: Huang, Ying, et al.
Publicado: (2020)

Checkpoint inhibitors in hematological malignancies
por: Ok, Chi Young, et al.
Publicado: (2017)

The Role of Genetic Polymorphisms in High-Dose Methotrexate Toxicity and Response in Hematological Malignancies: A Systematic Review and Meta-Analysis
por: Song, Zaiwei, et al.
Publicado: (2021)

Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis
por: Liang, Jiaqi, et al.
Publicado: (2020)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis
por: Pattanaik, Smita, et al.
Publicado: (2019)

Immunogenic Cell Death in Hematological Malignancy Therapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis
por: Gao, Chong, et al.
Publicado: (2018)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
por: Shu, Yamin, et al.
Publicado: (2022)

Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.
por: Parchment, R E
Publicado: (1998)

Financial toxicity in hematological malignancies: a systematic review
por: Ouchveridze, Evguenia, et al.
Publicado: (2022)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
por: David, John M., et al.
Publicado: (2019)

Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis
por: Ohashi, Takuma, et al.
Publicado: (2023)

The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis
por: Xu, Dongmei, et al.
Publicado: (2020)

Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Xuewen, et al.
Publicado: (2020)

Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis
por: Cui, Peng-Fei, et al.
Publicado: (2017)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dgrcjqinfcp44l700fktb4il0f